Legal Action Filed Against Novo Nordisk Over Misleading Growth Claims

Investor Notice: Large Losses in Novo Nordisk Shares May Be Subject to Legal Action NEW YORK, August 4, 2025 — Bernstein Liebhard LLP has announced that a class action lawsuit has been filed on behalf of investors who bought shares of Novo Nordisk A/S (NYSE: NVO) between May 7 and July 28, 2025. The lawsuit claims that the company made false statements regarding the growth prospects of its diabetes and obesity medication, GLP-1. Investors experiencing significant losses are encouraged to contact Bernstein Liebhard LLP to discuss their legal rights. Those interested in serving as lead plaintiffs must submit their applications by September 30, 2025. Participation in the case is on a contingency fee basis, meaning no upfront costs for shareholders. For more information or to get involved, investors can visit the firm's website, email Investor Relations Manager Peter Allocco at [email protected], or call (212) 951-2030. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for clients, including individual investors and major pension funds. The firm has received numerous accolades for its litigation work. Please note: This is an attorney advertisement. Prior results do...